Unknown

Dataset Information

0

Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.


ABSTRACT:

SUBMITTER: Jakob T 

PROVIDER: S-EPMC8095056 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.

Jakob Tina T   Tesfamariam Yonas Mehari YM   Macherey Sascha S   Kuhr Kathrin K   Adams Anne A   Monsef Ina I   Heidenreich Axel A   Skoetz Nicole N  

The Cochrane database of systematic reviews 20201203


<h4>Background</h4>Different bone-modifying agents like bisphosphonates and receptor activator of nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men with prostate cancer and bone metastases to prevent skeletal-related events (SREs). SREs such as pathologic fractures, spinal cord compression, surgery and radiotherapy to the bone, and hypercalcemia lead to morbidity, a poor performance status, and impaired quality of life. Efficacy and acceptability of the bon  ...[more]

Similar Datasets

| S-EPMC5784941 | biostudies-literature
| S-EPMC3493858 | biostudies-other
| S-EPMC4999580 | biostudies-literature
| S-EPMC3227909 | biostudies-other
| S-EPMC3684567 | biostudies-literature
| S-EPMC6990736 | biostudies-literature
| S-EPMC378510 | biostudies-literature
| S-EPMC5173066 | biostudies-literature
| S-EPMC1448165 | biostudies-literature
| S-EPMC6702312 | biostudies-literature